Long-term experience with the approved autologous anti-CD19 CAR-T cell therapies axicabtagene ciloleucel [9], tisagenlecleucel [10], and lisocabtagene maraleucel [11] confirms the curative potential of CAR-T in R/R aggressive large B-cell lymphomas (LBCL), including diffuse LBCL (DLBCL). The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.